A study to understand the differences in the cell cycle phase distribution and establish dormancy signature in patients on sequential vsconcurrent chemo-endocrine therapy in hormone receptor positive and HER2 negative non-metastatic breast cancer
Phase 3
- Conditions
- Health Condition 1: C509- Malignant neoplasm of breast of unspecified site
- Registration Number
- CTRI/2022/07/044399
- Lead Sponsor
- Tata Memorial Centre
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1.Patients undergoing treatment in Consequence study CTRI/2018/09/015643
2. Non-metastatic, biopsy proven breast cancer
ER and/or PR positive HER2 negative.
3. Age > 18 yrs
4. Fit to receive chemotherapy
5. Written, informed consent
6. Planned to receive both chemo and endocrine therapy in the adjuvant or neo-adjuvant setting
Exclusion Criteria
1.Pregnant or lactating women
2.Patients who are candidates to receive only 3.endocrine treatment (low risk of recurrence)
4.Inflammatory breast carcinoma
5.Women who have received prior chemo/hormonal therapy for breast cancer
6.Co-existing non-breast malignancy (such as hematolymphoid/ovarian cancer)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method